Navigation Links
Dr. Wayne Hachey Joins Protein Sciences' Leadership Team
Date:2/20/2013

MERIDEN, Conn., Feb. 20, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that Wayne Hachey , DO (Colonel, U.S. Army, ret.) has joined the Company's management as Head, Government and Clinical Affairs.  Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy.  He was also responsible for developing the overarching DoD mitigation response to pandemic influenza and directed the implementation of that policy during the 2009 H1N1 pandemic.  Most recently, Dr. Hachey served as the Chief of Public Health for the 1st Medical Brigade in Afghanistan where he provided public health leadership to protect over 98,000 U.S. troops.  He is board certified in Public Health, Pediatrics and Neonatal-Perinatal Medicine and has won numerous awards, including the Defense Meritorious Service Medal, Meritorious Service Medal, NATO (Afghanistan) and Afghanistan Campaign Medal and Unit Combat Patch. 

Dr. Manon Cox , MBA, President and CEO of Protein Sciences commented, "We are delighted to welcome Dr. Hachey to our team."  She added, "In his new role, his primary responsibility will be to play a key role in our Company's interactions with government agencies."

Dr. Hachey will represent Protein Sciences at the following meetings this week where the Company's revolutionary new influenza vaccine Flublok® will be presented:

The Advisory Committee on Immunization Practices (ACIP) Meeting
February 20-21, 2013
CDC, Atlanta, GA

2013 AAAAI Annual Meeting
February 22-26, 2013
San Antonio, TX

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most.  BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.

On January 16, the FDA approved Flublok, a novel influenza vaccine for the prevention of influenza in adults aged 18-49 years old. The FDA has called Flublok a revolutionary vaccine as no eggs or live influenza virus is used in its manufacturing process. In addition, the product does not contain a preservative (e.g., thimerosal), latex, adjuvants or other additives. 

Learn more at www.proteinsciences.com and www.flublok.com.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
2. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
3. Robert Farrell Joins Bionovos Board of Directors
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
6. First Choice Rehabilitation Specialists Joins Select Medical
7. Excel Life Sciences Joins DATATRAKs Connect Partner Program
8. Marina Biotech, Inc. Joins OTCQX
9. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
10. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
11. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... Phase 3 open-label two-year study of rufinamide, which ... the American Epilepsy Society (AES) held from December ... Analysis of final two-year safety, tolerability and cognitive ... with rufinamide experienced similar safety and tolerability profiles, ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
(Date:12/2/2016)... OAKS, Calif. , Dec. 2, 2016 Amgen ... AGN ) today announced the submission of a Marketing ... ABP 215, a biosimilar candidate to Avastin ® (bevacizumab). ... application submitted to the EMA. "The submission ... as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):